Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24493635 | 1.00 | CNR1 (0.52) | CNR1ALDH1A1CNR2FAAHMAPT | |
| SCHEMBL4602550 | 0.89 | DNM1 (0.41) | CNR1ALDH1A1CNR2FAAH | |
| SCHEMBL21235635 | 0.85 | ALDH1A1 (0.43) | CNR1ALDH1A1CNR2FAAHMAPT | |
| SCHEMBL2640807 | 0.85 | ALDH1A1 (0.43) | CNR1ALDH1A1CNR2FAAHMAPT | |
| SCHEMBL28862599 | 0.84 | ALDH1A1 (0.56) | CNR1ALDH1A1CNR2FAAHMAPT | |
| SCHEMBL19691883 | 0.84 | CNR1 (0.41) | CNR1ALDH1A1CNR2FAAHMAPT | |
| SCHEMBL19691884 | 0.84 | CNR1 (0.41) | CNR1ALDH1A1CNR2FAAHMAPT | |
| SCHEMBL7108549 | 0.82 | CNR1 (0.62) | CNR1ALDH1A1CNR2FAAHMAPT | |
| SCHEMBL17791303 | 0.82 | ALDH1A1 (0.43) | CNR1ALDH1A1CNR2FAAHMAPT | |
| SCHEMBL1934507 | 0.82 | ALDH1A1 (0.43) | CNR1ALDH1A1CNR2FAAHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2355658-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2017-09-27 | — | — | EP | disclosed |
| US-9764036-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-09-19 | — | — | US | disclosed |
| US-20160213785-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-07-28 | — | — | US | disclosed |
| US-20120095075-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213785-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | CNR1 1857/4885ALDH1A1 3880/4885CNR2 1808/4885 |
| US-20120095075-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | CNR1 1866/4885ALDH1A1 3847/4885CNR2 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.